4. CONCLUSIONS
Using the HAL9/10 libraries, we were able to select antibodies with high affinity for KLK7, and they also showed a high capacity to inhibit the proteolytic activity of this targeted enzyme. These recombinant antibodies were incorporated in a drug delivery system that was generated from poloxamers, and we demonstrated the viability of the system to encapsulate and deliver the antibodies, showing satisfactory pharmacological parameters for LUP-37A10 and LUP-37C11 in formulation F1 and LUP-37D11 in formulation F2. Our work has combined phage display and drug delivery methodologies to generate new molecules and formulations with potential for use in therapies for the pathologies in which KLK7 appears to be involved.